Mode
Text Size
Log in / Sign up
N/A N=602

Early Risk Stratification in ED Chest Pain Patients

Acute Coronary Syndrome

Enrolled (actual)
602
Serious AEs
4.3%
Results posted
Apr 2021
Primary outcome: Primary: Number of Patients With Major Adverse Cardiac Event — 42; 0; 437; 123 Participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Thrombolysis in myocardial infarction score (Other); routine blood test for hs-cTnT (Biological); HEART score (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Chinese University of Hong Kong
Primary completion
Oct 2014

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Patients With Major Adverse Cardiac Event
42; 0; 437; 123
SECONDARY
Number of Safety Major Adverse Cardiac Event
31; 0
SECONDARY
Number of Effecacy MACE
26; 0

Summary

In the management of adult chest pain patients presenting to an Emergency Department (ED) with suspected acute coronary syndrome (ACS), we aimed to evaluate the diagnostic accuracy of the combined use of a modified Thrombolysis in Myocardial Infarction (TIMI) score and a modified HEART score with high-sensitive cardiac troponin T (hs-cTnT) to rule out major adverse cardiac events (MACE) in 30-days.

Eligibility Criteria

Inclusion Criteria

  • Aged 18 years or over
  • Chest pain within 24 hours of ED presentation
  • Suspected with ACS

Exclusion Criteria

  • No cardiac chest pain based on clinical assessment
  • Hemodynamic or clinical instability (SBP<90 mmHg, clinically significant atrial/ventricular arrhythmias)
  • Initial ECG suggestive of ACS, Acute Myocardial Infarction or other abnormality requiring admission to hospital
  • Previous coronary artery bypass grafting or coronary stent implantation
  • Women with known or suspected pregnancy
  • Unable or unwilling to provide informed consent
  • Unable to be contacted after discharge
  • Contraindication to β-blockade if prescription of β-blockade is required due to a resting heart rate over 80 beats per minute
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02364271). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search